Agilux Laboratories Hires New Senior Director to Lead Pharmacology Operations

Agilux Laboratories Hires New Senior Director to Lead Pharmacology Operations

WORCESTER, Mass.--(BUSINESS WIRE)--Agilux Laboratories, a leading provider of Drug Metabolism and Pharmacokinetics (DMPK) services to pharmaceutical and biotechnology firms, is pleased to announce that Geeta Sharma, Ph.D. has joined the Agilux team as Senior Director, Pharmacology. In this role, Dr. Sharma will lead the Pharmacology group and will initially be focused on developing and launching non-GLP discovery oncology services. Dr. Sharma will also serve as a member of the senior management team.

"We are very pleased to have Dr. Sharma join our team here at Agilux"
Dr. Sharma has more than 15 years of experience in Drug Discovery in multiple therapeutic areas including oncology, infectious diseases, metabolic disorders, and inflammation. She has led discovery programs that have successfully translated to clinical candidates. She has published more than 15 research articles and has contributed to 11 patents. Most recently, Dr. Sharma was Senior Director, Pharmacology at Forma Therapeutics (Massachusetts-based company) at their Singapore location. Prior to this, Dr. Sharma has held roles of increasing responsibility at Combinatorx Singapore and Ranbaxy Laboratories, LTD.

"We are very pleased to have Dr. Sharma join our team here at Agilux," said Jim Jersey, President and CEO. "Dr. Sharma brings to us extensive knowledge and industry experience in discovery pharmacology and we look forward to her contributions and guidance in adding oncology pharmacology services to complement our continually expanding portfolio of discovery services. Given the industry's increasing focus on oncology therapeutic discovery and development within R&D, we are excited to offer these new services to our clients."

Dr. Sharma added, "I am excited to be an integral part of the team here at Agilux at a time when the discovery efforts in oncology are reaching their peak in the pharmaceutical industry. I look forward to leveraging Agilux's excellent infrastructure, systems and client rapport to set up and establish new capabilities that can help the industry expedite their discovery programs."

About Agilux Laboratories Inc.

Agilux Laboratories Inc., with over 90 employees and greater than 50,000 square feet of facility space, is a leading New England-based contract research organization (CRO) that has developed into one of the fastest growing CRO's in the Boston/Cambridge biotech arena. Agilux Labs is driven by its ability to offer "Better Data Faster" across a broad range of services supporting drug discovery, pre-clinical and clinical services. Our full range of Drug Metabolism and Pharmacokinetic services, include fit-for-purpose rapid turnaround LC-MS/MS Bioanalysis, In-Vivo PK, and In-Vitro Assay services. With corresponding clinical site support, GLP LC-MS/MS Bioanalytical services are also provided to support regulated pre-clinical and clinical studies. To learn more, please visit us at www.agiluxlabs.com.

Contacts

Steve Guyan, 508-753-5000
MS, Vice President, Sales and Marketing
[email protected]
Fax: 508-630-1679

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.